Jornada La Salud de las Mujeres y las Mujeres en Salud
Apertura Institucional Presentación Conferencia Magistral Mesa Redonda
XVII Jornadas de Primavera SADECA
Bienvenida y Apertura Mesa 1: Efecto Red Nuevos paradigmas en gestión del conocimiento Conferencia Final
Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer
Survival for breast cancer (BC) is lower in eastern than northern/central Europe, and in older than younger women. We analysed how comorbidities at diagnosis affected whether selected standard treatments (STs) were given, across Europe and over time, also assessing consequences for survival/relapse. We analysed 7,581 stage I/IIA cases diagnosed in 9 European countries in 2009−13,…
Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia
Spain has a reference price system (RPS) for off-patent medicines since 1997. In addition, from 2012, Andalusia is running a series of tenders for procuring off-patent medicines dispensed by community pharmacies, for those medicines included in the system of homogenous clusters within the national reference price system. Such tenders offer additional savings to the regional…
Nuria Malats
Minuto Experto 121
Conocimientos y actitudes de los médicos de Atención Primaria de Andalucía (España) sobre la detección de personas con riesgo elevado de cáncer de mama y colorrectal
Objetivos Explorar los conocimientos y las actitudes de los médicos de Atención Primaria de Andalucía sobre la detección de personas con riego elevado de cáncer de mama y colorrectal y el cáncer hereditario. Métodos Estudio descriptivo transversal a partir de una encuesta de opinión on line. Cuestionario de 24 preguntas. Para el análisis estadístico se…
Soledad Benot
Minuto Experto 120
Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort
Background Receptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growth and spread in experimental models. Binding of RANK ligand (RANKL) to RANK activates signaling, which is inhibited by osteoprotegerin (OPG). We have previously shown that circulating soluble RANKL (sRANKL) and OPG are associated with breast cancer risk. Here we extend these findings…